Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products ... Oncology, Takeda Consulting or Advisory Role: AstraZeneca, Ono ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

The Series A was led by founding investor Versant Ventures with participation from Mubadala Capital, Bristol Myers Squibb, ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Fangzhou Inc, a pioneer in internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (BMS) China, a global biopharmaceutical company with a robust research and ...